Aplicaciones Innovadoras De La Robótica Y Biomédica En La Salud Pública Durante La Pandemia Del COVID-19: Robotics and Biomedical Innovative Applications in Public Health during the COVID-19 Pandemic

In the current situation of the large-scale spread of COVID-19, whereas contagion increases, the role of robots (designed with Teleoperation and Artificial Intelligence technology) in society becomes essential, because they need to be used in hospital settings, urban environment, and also using Telemedicine consultancy to have access to all communities in the world, in order to avoid the spread of the virus. In addition, multidisciplinary work could be promoted, among the engineering and health sciences in the American Continent and Worldwide, through research, development and innovation projects in Biomedical Engineering, with the proposal of being ready to face a global and national emergency like the current Pandemic caused by SARS-CoV-2.En la situación actual de propagación a gran escala del COVID-19, mientras aumenta el contagio, el papel de los robots (diseñados con tecnología de Teleoperación e Inteligencia Artificial) en la sociedad se vuelve fundamental, pues necesitan ser utilizados en entornos hospitalarios, entornos urbanos, y también utilizar la consultoría de Telemedicina para tener acceso a todas las comunidades del mundo, a fin de evitar la propagación del virus. Además, se podría promover el trabajo multidisciplinario, entre la ingeniería y las ciencias de la salud en el Continente Americano y a nivel mundial, a través de proyectos de investigación, desarrollo e innovación en Ingeniería Biomédica, con la propuesta de estar preparados para enfrentar una emergencia global y nacional como la actual Pandemia. causado por el SARS-CoV-2

La revolución de la cirugía robótica en latino américa y la futura implementación en el sistema de salud del perú: The revolution of robotic surgery in latin america and the future implementation in the healthcare system of Peru

Surgery has marked a milestone in history, from its origins and for many centuries, this specialty a close relationship with the healing of wounded in combat case presented during the beginning of Open Surgery, with the so-called Trepanaciones Craniaas that were made in the 700 a.C. - 200 AD for the Paracas Culture in Peru; with the During the time the techniques that were complemented with the use were perfected of new instruments and the development of technology leading to a revolution in the various Surgical specialties   DOI 10.25176/RFMH.v19.n1.1800La Cirugía ha marcado un hito en la historia, desde sus orígenes y durante muchos siglos, esta especialidad estaba en estrecha relación con la curación de heridos en combate, una gran evidencia se denota en el caso presentado durante los inicios de la Cirugía Abierta, con las intervenciones llamadas Trepanaciones Craneanas que fueron realizadas en los años 700 a.C. – 200 d.C. por la Cultura Paracas en el Perú; con el transcurso del tiempo se fueron perfeccionando diversas técnicas que se complementaron con el uso de nuevos instrumentos y el desarrollo de la tecnología dando lugar a una revolución en las diversas especialidades quirúrgicas.   DOI 10.25176/RFMH.v19.n1.180

INNOVACIONES INTERNACIONALES EN ROBÓTICA MÉDICA PARA MEJORAR EL MANEJO DEL PACIENTE EN PERÚ: INTERNATIONAL INNOVATIONS IN MEDICAL ROBOTICS TO IMPROVE THE PATIENT MANAGEMENT IN PERU

Surgical Engineering Society conducted a research, the First Review as the pioneers in LATAM, since year 2015, which develops the topic of the latest Medical Robotics technologies created in North América, Europe and Asia, which are imported to apply in the Healthcare System of Peru and Latin America. The robotic systems for surgery, rehabilitation and assistance are presented covering the description of control design and technical specifications. Besides, the patient management using robots is analyzed with diagnosis, prognosis and treatment tools. The process to evaluate the new inventions of robotic devices and bring to the market is introduced where three stages are shown as the following: innovation, regulatory affairs and biomedical application. Moreover, there is a high percentage of population with disability in Latin America, therefore, it is necessary that more biomedical scientists be specialized in robotics to start developing new ideas to improve the patient management. Finally, the new technologies created in Latin America must be affordable, simply and efficient in order to support the healthcare economic situation in the continent and give the best quality standards to improve treatment outcomes on patients.Surgical Engineering Society realizó una investigación, la primera revisión como pioneros en LATAM, desde el año 2015, que desarrolla el tema de las últimas tecnologías de robótica médica creadas en América del Norte, Europa y Asia, que se importan para aplicarlas en el sistema de salud de Perú y América Latina Los sistemas robóticos para cirugía, rehabilitación y asistencia se presentan cubriendo la descripción del diseño del control y las especificaciones técnicas. Además, el manejo del paciente mediante robots se analiza con herramientas de diagnóstico, pronóstico y tratamiento. El proceso para evaluar los nuevos inventos de los dispositivos robóticos y llevarlo al mercado se introduce donde en las tres etapas que se muestran a continuación: innovación, asuntos regulatorios y aplicación biomédica. Además, hay un alto porcentaje de población con discapacidad en América Latina, por lo tanto, es necesario que más científicos biomédicos se especialicen en robótica para comenzar a desarrollar nuevas ideas y mejorar el manejo del paciente. Finalmente, las nuevas tecnologías creadas en América Latina deben ser asequibles, simples y eficientes para apoyar la situación económica de la atención médica en el continente y brindar los mejores estándares de calidad para mejorar los resultados del tratamiento en los pacientes

Advancements in dementia research, diagnostics and care in Latin America : highlights from the 2023 Alzheimer's association international conference satellite symposium in Mexico City

While Latin America (LatAm) is facing an increasing burden of dementia due to the rapid aging of the population, it remains underrepresented in dementia research, diagnostics and care. In 2023, the Alzheimer’s Association hosted its eighth Satellite Symposium in Mexico, highlighting emerging dementia research, priorities, and challenges within LatAm. A wide range of topics were covered, including epidemiology, social determinants, dementia national plans, risk reduction, genetics, biomarkers, biobanks, and advancements in treatments. Large initiatives in the region including intra-country support showcased their efforts in fostering national and international collaborations; genetic studies unveiled the unique genetic admixture in LatAm; emerging clinical trials discussed ongoing culturally specific interventions; and the urgent need to harmonize practices and studies, improve diagnosis and care and implement affordable biomarkers in the region was highlighted

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF.

AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy. The mean (standard deviation) age was 69.8 (11.4) years, 43.8% were women, and the mean CHA2DS2-VASc score was 3.3 (1.6); 60.8% of patients were prescribed anticoagulant therapy with/without antiplatelet (AP) therapy, 27.4% AP monotherapy, and 11.8% no antithrombotic therapy. At 2-year follow-up, all-cause mortality, stroke/SE, and major bleeding had occurred at a rate (95% confidence interval) of 3.83 (3.62; 4.05), 1.25 (1.13; 1.38), and 0.70 (0.62; 0.81) per 100 person-years, respectively. Rates for all three major events were highest during the first 4 months. Congestive heart failure, acute coronary syndromes, sudden/unwitnessed death, malignancy, respiratory failure, and infection/sepsis accounted for 65% of all known causes of death and strokes for <10%. Anticoagulant treatment was associated with a 35% lower risk of death. CONCLUSION: The most frequent of the three major outcome measures was death, whose most common causes are not known to be significantly influenced by anticoagulation. This suggests that a more comprehensive approach to the management of NVAF may be needed to improve outcome. This could include, in addition to anticoagulation, interventions targeting modifiable, cause-specific risk factors for death. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Design of Biomedical Soft Robotic Device for Lower Limbs Mechanical Muscle Rehabilitation and Electrochemical Monitoring under Reduced-Gravity Space Environment

Space travel is one of humanity's most fantastic aspirations. However, space is the most dangerous environment due to extreme conditions. Reduced-gravity generates disuse muscle atrophy and impaired blood circulation in lower limbs. Therefore, this paper proposes a new biomedical soft robotic system to improve muscle development and promote blood circulation by applying energetically efficient mechanical stimulation to the soft tissues of the astronaut's lower limb and, additionally, to monitor their performance by cotton-based carbon nanotubes biosensors. The computational mechanical simulations performed show a maximum increase in energy optimisation of 89% and a maximum safety factor of 2.75. These preliminary results suggest an increase in the efficiency and safety of the soft robotic device